Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)

NCT01709500 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

DRUG: LMT (atorvastatin, simvastatin, or rosuvastatin)
DRUG: alirocumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]